EGFR and non-small cell lung carcinoma: In the first set of experiments, we compared the susceptibility to osimertinib in AXL-high-expressing (PC-9, PC-9/GXR, and HCC4011) and AXL-low- expressing (HCC4006, HCC827, and H3255) EGFR-mutated NSCLC cell lines in vitro (Fig. 1 a, b).